Supplementary materials

for

An in vitro investigation of the antiproliferative and antimetastatic effects of levosimendan: Potential drug repurposing for cervical cancer

Zsuzsanna Schelz †, Hiba F. Muddather †, Fatemeh Sheihaki Jaski, Noémi Bózsity and István Zupkó *


Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary; schelz.zsuzsanna@szte.hu (Z.S.); hiba.161991@hotmail.com (H.F.M.); jaski.sheihaki.fatemeh@gmail.com (F.S.J.); bozsity-farago.noemi@szte.hu (N.B.)

* Correspondence: zupko.istvan@szte.hu

† These authors contributed equally to this work.


Figure S1. Growth inhibitory effects of levosimendan on cervical cancer cell lines and non-cancerous human fibroblast cells (MRC-5):

A. First experiment:



Data presents dose-response curves as the average percentages of cell growth inhibition ± SEM on C33A cells, 72 h post-incubation, measured by a standard MTT assay.

B. Second independent experiment:




Data presents dose-response curves as the average percentages of cell growth inhibition ± SEM on C33A cells, 72 h post-incubation, measured by a standard MTT assay.


Figure S2. Representative histograms for C33A cervical cell line treated with levosimendan:

A. **24 h post-incubation:**


Control




30 µM levosimendan



45 µM levosimendan




60 μM levosimendan




B. 48 h post-incubation:


Control



30 μM levosimendan



45 μM levosimendan



60 μM levosimendan

